Ruthenium complexes anti-cancer

Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, Jaehde U (2009) Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anti-Cancer Drugs 20 97-103... 

Bacac M, Hotze ACG, van der Schilden K, Haasnoot JG, Pacor S, Alessio E, Sava G, Reedijk J (2004) The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity an NMR evaluation. J Inorg Biochem 98 402-412... 

Whereas neither ferrocene nor OH-Tam had any effect on the ER-negative cells at 1 pM, the combination of the two motifs yielded highly toxic molecules. With the notable exception of a few ruthenium complexes [73,74], the anti-cancer properties... 

As the mechanism of NAMI-A begins to unfold, it has been shown that the drug may not need to enter the ceU in order to have a therapeutic effect hence transferrin delivery to the ceU interior may not be part of the low toxicity of this drug. NAMI-A causes changes in the extracellular matrix around the cancer cells such that they are contained and suffocated. Further studies have shown that certain ruthenium(ll)-arene complexes, such as those in Fig. 6a and b, also demonstrate remarkably low toxicity and anti-cancer/antimetastasis activity, despite the fact that these complexes enter the... 

The Ru(in) compounds [HIm][trans-RuCl4(Im)(DMSO-5)] and [HInd][tran5-RuCl4(Ind)2] (Im = imidazole, Ind = indazole, Eig. 22.22) have completed phase I clinical trials as anti-cancer drugs. The former complex selectively targets metastases of solid tumours. The range of ruthenium-based compounds that exhibits anti-cancer activity includes organometallic ruthenium(II) complexes. ... 

---